Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
29.06
+0.55 (1.93%)
Sep 29, 2026, 9:57 AM EDT - Market open
Adaptive Biotechnologies Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 308.08 | 276.98 | 178.96 | 170.28 | 185.31 | 154.34 | |
Revenue Growth | 50.13% | 54.77% | 5.10% | -8.11% | 20.06% | 56.88% |
Cost of Revenue | 163.46 | 165.13 | 175.03 | 197.67 | 199.67 | 191.64 |
Gross Profit | 144.62 | 111.85 | 3.92 | -27.39 | -14.36 | -37.3 |
Selling, General & Admin | 180.38 | 167.27 | 157.57 | 172.51 | 184.13 | 169.97 |
Amortization of Goodwill & Intangibles | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 |
Operating Expenses | 182.08 | 168.97 | 159.27 | 174.21 | 185.83 | 171.67 |
Operating Income | -37.46 | -57.12 | -155.34 | -201.61 | -200.19 | -208.97 |
Interest Expense | -11.51 | -11.78 | -11.58 | -13.8 | -4.24 | - |
Interest & Investment Income | 7.66 | 6.93 | 6.33 | 6.35 | 4.8 | 8.9 |
EBT Excluding Unusual Items | -41.31 | -61.97 | -160.6 | -209.06 | -199.63 | -200.07 |
Merger & Restructuring Charges | - | - | -7.21 | - | - | - |
Gain (Loss) on Sale of Investments | 1.05 | 2.51 | 8.21 | 9.18 | -0.74 | -7.23 |
Asset Writedown | - | - | - | -25.43 | - | - |
Pretax Income | -63.99 | -59.46 | -159.6 | -225.3 | -200.37 | -207.3 |
Earnings From Continuing Operations | -63.99 | -59.46 | -159.6 | -225.3 | -200.37 | -207.3 |
Minority Interest in Earnings | 0.14 | -0.04 | 0.1 | 0.05 | 0.18 | 0.02 |
Net Income | -63.85 | -59.5 | -159.49 | -225.25 | -200.19 | -207.28 |
Net Income to Common | -63.85 | -59.5 | -159.49 | -225.25 | -200.19 | -207.28 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 155 | 152 | 147 | 144 | 143 | 140 |
Shares Outstanding (Diluted) | 155 | 152 | 147 | 144 | 143 | 140 |
Shares Change | 4.11% | 3.14% | 1.88% | 1.31% | 1.54% | 6.96% |
EPS (Basic) | -0.41 | -0.39 | -1.08 | -1.56 | -1.40 | -1.48 |
EPS (Diluted) | -0.41 | -0.39 | -1.08 | -1.56 | -1.40 | -1.48 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -24.03 | -48.95 | -98.88 | -167.02 | -200.29 | -254.47 |
Free Cash Flow Per Share | -0.15 | -0.32 | -0.67 | -1.16 | -1.41 | -1.81 |
Gross Margin | 46.94% | 40.38% | 2.19% | -16.09% | -7.75% | -24.17% |
Operating Margin | -12.16% | -20.62% | -86.80% | -118.40% | -108.03% | -135.39% |
Profit Margin | -20.73% | -21.48% | -89.12% | -132.28% | -108.03% | -134.30% |
Free Cash Flow Margin | -7.80% | -17.67% | -55.25% | -98.09% | -108.09% | -164.87% |
EBITDA | -21.33 | -39.29 | -136.09 | -179.38 | -179.27 | -195.01 |
EBITDA Margin | -6.92% | -14.19% | -76.05% | -105.34% | -96.74% | -126.35% |
D&A For EBITDA | 16.13 | 17.83 | 19.26 | 22.23 | 20.92 | 13.95 |
EBIT | -37.46 | -57.12 | -155.34 | -201.61 | -200.19 | -208.97 |
EBIT Margin | -12.16% | -20.62% | -86.80% | -118.40% | -108.03% | -135.39% |
Advertising Expenses | - | 4.1 | 6.1 | 8.6 | 13.7 | - |